<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02725528</url>
  </required_header>
  <id_info>
    <org_study_id>PSI 2016-03</org_study_id>
    <nct_id>NCT02725528</nct_id>
  </id_info>
  <brief_title>Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's</brief_title>
  <acronym>EXTEND</acronym>
  <official_title>A Multi-Center, Randomized Controlled Trial Comparing The Clinical Effectiveness and Cost-Effectiveness of Collagenase Injection (Xiaflex) and Palmar Fasciectomy in the Management of Dupuytren's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-centre, pragmatic randomized controlled trial to compare both&#xD;
      the clinical effectiveness and cost-effectiveness of collagenase injections (CI) versus&#xD;
      limited palmar fasciectomy (LPF) to determine if collagenase is a superior treatment in terms&#xD;
      of improved quality of life and reducing recurrence of the disease without serious&#xD;
      complications. Since collagenase injections are costly it is also important to know if this&#xD;
      novel intervention is cost-effective from the patient, Ministry of Health and societal&#xD;
      perspectives.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 8, 2017</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>health-related quality of life (HRQL) using the Michigan Hand Outcomes Questionnaire (MHQ)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HRQL measured with the Health Utility Index Mark 3 (HUI3) of Health)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQL measured with the Unité Rhumatologique des Affections de la Main (URAM)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQL measured with the Southampton Dupuytren's Scoring Scheme (SDSS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality Adjusted Life Years (QALY) measured with the Health Utility Index Mark 3 (HUI3)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported healthcare utilization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of motion (ROM) of hand joints</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rates</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Dupuytren's Disease</condition>
  <arm_group>
    <arm_group_label>collagenase injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This procedure will be performed either in a minor procedure room or the hand clinic as per surgeon's routine practice. Collagenase will be administered with or without local anesthesia. As this is a pragmatic study there may be more than one digit injected at a time just as surgery occurs on more than one digit at a time. A recently published study by Gaston et al confirmed that two concurrent injections of collagenase to 2 affected joints in the same hand are generally well tolerated and the frequency of most adverse events (AEs) is similar to those reported in studies that use single sequential injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>limited palmar fasciectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Dupuytren's cord will be excised under local anesthesia in a minor procedure room setting or main operating room under local or general anesthetic depending on the complexity of the disease and the surgeon's routine. As this is a pragmatic study comparison of collagenase injections (novel intervention) to limited palmar fasciectomy as it is actually presently performed in all settings academic or community (local in minor room or general/local anesthetic in the main operating room) will be examined. Surgery will be performed according to the operating surgeon's preferred technique i.e. zig-zag Brunner incision or straight incision with z-plasty closure of the skin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>collagenase injection</intervention_name>
    <description>injection</description>
    <arm_group_label>collagenase injection</arm_group_label>
    <other_name>enzyme, collagenase clostridium histolyticum, xiaflex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>limited palmar fasciectomy</intervention_name>
    <description>surgery</description>
    <arm_group_label>limited palmar fasciectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Canadian Citizen&#xD;
&#xD;
          2. 18 years of age or older&#xD;
&#xD;
          3. Dupuytren's contracture of the metacarpophalangeal (MCP) joint or of the proximal&#xD;
             interphalangeal (PIP) joint with a fixed flexion contracture of 20º or greater in at&#xD;
             least 1 finger (not the thumb)&#xD;
&#xD;
          4. Demonstrated inability to simultaneously place the affected finger and palm flat on a&#xD;
             table&#xD;
&#xD;
          5. Able to understand and communicate in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment of the primary joint within 90 days of study inclusion&#xD;
&#xD;
          2. Patients undergoing any concomitant procedure on the same hand (e.g. carpal tunnel&#xD;
             release, stenosing tenosynovitis release)&#xD;
&#xD;
          3. Persistent extension deficit from a previous surgery of the same digit&#xD;
&#xD;
          4. Any chronic muscular or neuromuscular disorder affecting wrist or hand&#xD;
&#xD;
          5. Patient generally unfit for surgery&#xD;
&#xD;
          6. Patient with specific treatment preference&#xD;
&#xD;
          7. Bleeding disorder or recent stroke&#xD;
&#xD;
          8. Allergy to collagenase&#xD;
&#xD;
          9. Collagenase treatment or treatment with any investigational drug within 30 days of&#xD;
             study inclusion&#xD;
&#xD;
         10. Use of a tetracycline derivative within 14 days of first dose of study drug (because&#xD;
             tetracycline derivatives may inhibit the collagenolytic activity of mammalian&#xD;
             collagenase homologs [i.e., matrix metalloproteinases])&#xD;
&#xD;
         11. Pregnant or breast feeding patients&#xD;
&#xD;
         12. Patients who do not have insurance coverage for collagenase injections&#xD;
&#xD;
         13. Patients who are unable to provide informed consent or are unable to complete quality&#xD;
             of life questionnaires due to mental capacity or neuro-psychological problems.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Achilleas Thoma, MD MSc FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare / McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markham Stouffville Hospital</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L6B 0T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>679 Davis St. Suite 209</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halton Healthcare Services</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakville Trafalgar Hospital</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North York General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2J 1V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Achilleas Thoma</investigator_full_name>
    <investigator_title>Dr. Achllieas Thoma</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dupuytren Contracture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

